Drug Profile
Fospropofol - Eisai
Alternative Names: Aquavan®; Fospropofol disodium; GPI 15715; HX0507; Lusedra; PQ 1002Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ProQuest Pharmaceuticals
- Developer Eisai Co Ltd; West China Hospital Sichuan University; Yichang Humanwell Pharmaceutical
- Class Anaesthetics; Hypnosedatives; Phenols; Small molecules
- Mechanism of Action GABA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sedation
Most Recent Events
- 18 Feb 2021 No development reported - Phase-III for Sedation (In volunteers) in China (IV)
- 12 Feb 2018 Yichang Humanwell Pharmaceutical in collaboration with West China Hospital, Sichuan University completed a phase III trial in Sedation (In volunteers) in China (ChiCTR1800016329)
- 19 Jan 2018 Yichang Humanwell Pharmaceutical in collaboration with Sichuan University completes a phase III trial in Sedation (In volunteers) in China (ChiCTR1800016410)